0.98 (0.31)	1.04 (0.09)	1.06 (0.26)	1.04 (0.39)	1.14 (0.39)	Atypical Teratoid Rhabdoid Tumor
1 (0.98)	0.93 (0.05)	0.98 (0.82)	1.05 (0.75)	0.48 (0.2)	CRANIO, ADAM
1 (0.98)	0.93 (0.05)	0.98 (0.82)	1.05 (0.75)	0.48 (0.2)	Craniopharyngioma
1 (0.71)	1.01 (0.51)	1.03 (0.03*)	1.01 (0.38)	1.06 (0.51)	DMG, H3 K28
1.03 (0.02*)	0.98 (0.13)	0.87 (0.21)	0.97 (0.42)	0.92 (0.67)	Ependymoma
1.01 (0.77)	0.97 (0.08)	1.02 (0.89)	0.94 (0.3)	0.83 (0.44)	EPN, PF A
1.08 (<0.01*)	0.99 (0.81)	0.39 (0.02*)	0.99 (0.85)	1.12 (0.73)	EPN, ST ZFTA
0.62 (1)	1.53 (1)	3.48 (1)	NA (NA)	0 (1)	Germ cell tumor
NA (NA)	NA (NA)	NA (NA)	NA (NA)	NA (NA)	GNG/GNT, BRAF V600E
0.82 (0.75)	1.24 (0.7)	1 (1)	1.38 (0.67)	0.66 (0.69)	GNG/GNT, Other alteration
1.01 (0.44)	0.98 (0.12)	0.96 (0.23)	0.95 (0.12)	0.8 (0.1)	HGG, H3 WT
1.01 (0.38)	1 (0.78)	1.01 (0.43)	1 (0.73)	0.9 (0.1)	High–grade glioma OS Hazard Ratio 4
0 (0.9)	0.09 (1)	0 (0.99)	0 (1)	NA (NA)	LGG, BRAF fusion
NA (NA)	1.15 (1)	NA (NA)	0.12 (1)	1.93 (1)	LGG, BRAF V600E
1.11 (<0.01*)	0.89 (0.02*)	0.85 (0.33)	0.98 (0.69)	1.14 (0.81)	LGG, Other alteration
1 (NA)	1 (NA)	1 (NA)	1 (NA)	1 (NA)	LGG, WT
1.05 (<0.01*)	0.97 (0.19)	0.82 (0.04*)	0.97 (0.54)	1.23 (0.62)	Low-grade glioma
0.96 (0.47)	1.01 (0.68)	0.89 (0.12)	1.11 (0.08)	1.02 (0.89)	MB, Group3
1.01 (0.37)	1 (0.86)	0.98 (0.75)	0.98 (0.69)	1.07 (0.76)	MB, Group4
0.96 (0.38)	1 (0.99)	1.12 (0.22)	0.93 (0.08)	1.26 (0.52)	MB, SHH
1.05 (0.84)	3.8 (0.43)	1.12 (0.82)	NA (NA)	0.17 (0.35)	MB, WNT
1 (0.83)	1.01 (0.62)	0.97 (0.49)	1.02 (0.48)	1.04 (0.76)	Medulloblastoma
0.85 (0.75)	1.39 (0.58)	1.12 (0.58)	NA (NA)	0.59 (0.55)	Meningioma
1.11 (<0.01*)	1 (0.96)	0.93 (0.31)	1 (0.93)	0.99 (0.98)	Mesenchymal tumor
0.93 (0.73)	1.72 (0.33)	1.07 (0.77)	1.61 (0.45)	0.29 (0.16)	Mixed neuronal-glial tumor
0.8 (1)	1.44 (1)	3 (1)	NA (NA)	0.27 (1)	Schwannoma
PC1	PC2	PC3	PC4	PC5	_